Saxenda, Ozempic, and Mounjaro: a Comparative Analysis of The Weight Loss Medications and Their Side Effects in Najaf, Iraq
DOI:
https://doi.org/10.46966/msjar.v6i3.275Abstract
Background: Pharmacological management of obesity has occurred through weight loss injection, such as Saxenda, Ozempic, and Mounjaro. These agents control appetite, satiety and glucose metabolism that stimulate caloric intake and weight loss. Although they are generally safe, any drug has the possibility of causing side effects primarily the gastrointestinal ones and infrequent severe effects, such as pancreatitis. Purpose: This research was intended to determine the effectiveness of Saxenda, Ozempic and Mounjaro and their side effects in relation to the reduction of body weight in adults in Najaf, Iraq. Methodology: The study involved a cross-sectional study in the period between January and April 2025 in Najaf. Fifty adult patients who visited nutrition and obesity clinics were involved. The demographic, body weight, and side effect data collected was through self-administered questionnaires. The use of descriptive statistics, paired t-tests, ANOVA and regression analyses were used. Findings: The majority of them were women aged 20-45 years. The most common used (52%), Ozempic (30%), and Mounjaro (18%). There was a significant weight reduction (p < 0.01) with Mounjaro recording the highest mean reduction. The prevalence of gastrointestinal side effects was highest, but with a minor variation in drugs. The regression analysis showed that physical activity and type of medication played a major role in weight loss outcomes. Conclusion: Saxenda, Ozempic, and Mounjaro are viable in reducing weight in the short term. Mounjaro caused the weight loss to the maximum. The side-effects were generally mild. It is advisable to incorporate these medications with lifestyle changes in order to handle obesity in the best way possible.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Zainab Sajid Mohammed, Wijdan Rajh Hamza Al-Kraity
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
